AGER and Cognitive impairment: One study in a 400 patient cohort found that in patients with mild AD, oral administration of the RAGE antagonist TTP488 or PF-04494700 (or Azeliragon; vTv Therapeutics) demonstrated significant differences at month 18 on the ADAS-cog (Alzheimer's Disease Assessment Scale-Cognitive subscale), an established scale evaluating cognitive impairment in the assessment of AD (Burstein et al., 2014; Galasko et al., 2014).